Aptamer-conjugated gold nanoparticles offer a precise method for targeting muscle stem cells in Duchenne Muscular Dystrophy (DMD), addressing a major challenge in gene therapy. By ensuring microRNA therapies reach regenerative muscle cells with high specificity, this approach enhances treatment efficacy while minimizing off-target effects. Recent findings, published in Nature Communications, confirm that the platform is non-toxic and does not trigger immune reactions, marking a crucial step toward clinical translation and potential therapeutic applications.
https://www.nature.com/articles/s41467-024-55223-9